December 19, 2017
Approval granted several months ahead of the initial schedule Launch of HEMOBLAST™ Bellows in the United States expected over the summer in 2018 Saint-Priest, France, December 18, 2017 – Biom’Up, specialist in surgical hemostasis, announces today that it has received FDA marketing approval for HEMOBLASTTM Bellows, its flagship product, 7 months ahead of schedule. This pre-marketing...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge